YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
December 19, 2024 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially...
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26
December 16, 2024 08:30 ET
|
Ascendis Pharma
- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily...
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
December 12, 2024 16:01 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental...
Ascendis Pharma Reports Third Quarter 2024 Financial Results
November 14, 2024 16:01 ET
|
Ascendis Pharma
– YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 – TransCon CNP NDA submission for achondroplasia planned for Q1 2025...
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
November 07, 2024 16:01 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update on...
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
November 04, 2024 07:00 ET
|
Ascendis Pharma
- Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases - Once-monthly GLP-1 receptor agonist will be the collaboration’s...
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
September 30, 2024 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food &...
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
September 30, 2024 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year results from the Company’s ongoing Phase 2 PaTH Forward Trial of 57 adults with...
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
September 19, 2024 20:16 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares...
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
September 18, 2024 16:04 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has commenced an underwritten public offering of $300,000,000 of American Depositary...